• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Cardio3 BioSciences (C3BS) - Articles and news items

celyad

Cardio3 BioSciences announces results of annual shareholder assembly 2015; confirms name change to Celyad

Industry news / 6 May 2015 / Victoria White

All resolutions presented at Cardio3 BioSciences’ Annual Shareholder Assembly were duly passed including a name change for the Company to Celyad…

celyad

Cardio3 BioSciences becomes Celyad

Industry news / 16 April 2015 / Victoria White

Cardio3 BioSciences, a leader in engineered cell therapies, has announced its intention to change its corporate name to ‘Celyad’…

Cardio3 BioSciences (C3BS) Logo

Cardio3 Biosciences announces the nomination of three co-principal investigators for its chart-2 Phase iii clinical trial of C-Cure® for the treatment of heart failure

Industry news / 26 November 2014 / Cardio3 BioSciences

Cardio3 BioSciences announces the appointment of its three Co-Principal Investigators for the CHART-2 study (Congestive Heart Failure cArdiopoietic Regenerative Therapy), authorized in the United States by the FDA in January, and anticipated to start by the end of 2014…

Cardio3 BioSciences (C3BS) Logo

Cardio3 Biosciences appoints Dr. Warren Sherman as Chief Medical Officer

Industry news / 23 October 2014 / Cardio3 BioSciences

Cardio3 BioSciences announces the appointment of Dr. Warren Sherman as Chief Medical Officer, effective as of 1 November 2014…

Cardio3 BioSciences (C3BS) Logo

Cardio3 Biosciences receives authorization to enroll patients in Switzerland in its Phase iii clinical trial CHART-1

Industry news / 14 October 2014 / Cardio3 BioSciences

Cardio3 BioSciences announces it has received authorization from Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C-Cure® in Switzerland…

Cardio3 BioSciences (C3BS) Logo

Cardio3 Biosciences awarded preferred access rights to all Mayo Clinic Center for regenerative medicine portfolio

Industry news / 9 October 2014 / Cardio3 BioSciences

Cardio3 BioSciences announces the signing of a preferred access agreement with Mayo Clinic…

Cardio3 BioSciences (C3BS) Logo

Cardio3 BioSciences announces new business development strategy to broaden its product pipeline

Industry news / 1 October 2014 / Cardio3 BioSciences

Cardio3 BioSciences announces that it has recently increased its business development activities, building on its core expertise in cellular therapies and in cardiovascular diseases…

Cardio3 BioSciences (C3BS) Logo

Cardio3 Biosciences receives approval for the continuation of its chart-1 Phase iii clinical trial from the DSMB

Industry news / 16 September 2014 / Cardio3 BioSciences

Cardio3 BioSciences SA announces it has received the recommendation of the Data Safety and Monitoring Board (DSMB) to continue the CHART-1 clinical trial according to the original protocol…

Cardio3 BioSciences (C3BS) Logo

Cardio3 BioSciences appoints Dr. Alexander Milstein as Vice President of Clinical Development

Industry news, News / 21 August 2012 / Citigate Dewe Rogerson

C3BS announces the appointment of Dr Alexander Milstein…

Award Winning Mayo Clinic Scientist Joins Cardio3 BioSciences

Industry news, News / 14 July 2010 / Citigate Dewe Rogerson

Cardio3 BioSciences, announces that Dr. Atta Behfar is joining its research and development laboratories as Director for Advanced Research…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +